Co-immunolabeling for SUR1 and BAFF, CCL2 or NOS2 confirmed that astrocytes in MS lesions that express SUR1-TRPM4 channels also express these pathogenic molecules (Fig. 12). Here, CCL2 is linked to myeloid sarcoma.